The evidence base for peptide-driven weight loss is measured in months, not days. The major GLP-1 trials reported their headline results at 68–72 weeks, and the drugs' own labeled dose-escalation schedules take 16–20 weeks just to reach the full maintenance dose. For experimental research peptides, no comparable time-course data exist at all.
What the major trials actually measured
The best-documented timelines come from the large randomized trials of GLP-1–based medicines:
- STEP 1 (semaglutide 2.4 mg weekly, n=1,961): mean weight change of −14.9% vs −2.4% for placebo, measured at week 68 (Wilding et al., NEJM 2021).
- SURMOUNT-1 (tirzepatide, n=2,539): mean weight change of −15.0% to −20.9% depending on dose, vs −3.1% for placebo, measured at week 72 — a period that included a 20-week dose-escalation phase (Jastreboff et al., NEJM 2022).
Those headline percentages are endpoints, not week-one results. The trials were explicitly designed around a slow ramp followed by many months at the full dose, so the famous numbers describe what happened over well more than a year.
Why the first months look slow: titration
A detail that answers most "why isn't it working yet" searches: these medicines are not started at their full dose. Per the FDA labeling for Wegovy (semaglutide 2.4 mg), treatment begins at 0.25 mg weekly and steps up every 4 weeks — 0.25, 0.5, 1, then 1.7 mg — reaching the 2.4 mg maintenance dose only at week 17. The label frames this escalation as a way to reduce the risk of gastrointestinal adverse reactions. Tirzepatide's trial program was structured similarly, with dose escalation occupying the first 20 weeks of SURMOUNT-1.
This structure has a direct consequence for timelines: the early months of every trial weight-loss curve reflect sub-maximal dosing. Weight loss in the trials began during titration, but the steepest and largest changes accumulated after participants reached maintenance dosing.
There is also evidence that the process keeps going long after titration ends. In STEP 4, participants first completed a 20-week semaglutide run-in; those then randomized to continue the drug lost a further 7.9% of body weight between weeks 20 and 68, while those switched to placebo regained (Rubino et al., JAMA 2021). In other words, the trials show months of continued loss beyond the point many people would consider "waiting for it to work."
Why individual timelines vary
Trial curves are averages, and the spread around them is wide. Documented sources of variation include:
- Dose reached and tolerated — in trials, some participants stayed at lower doses because of side effects, which shifts both speed and magnitude.
- Adherence and interruptions — missed weeks and restarts flatten the curve (labels specify re-escalation after long gaps).
- Baseline biology — starting weight, diabetes status, and other medications all influenced trial outcomes; participants with type 2 diabetes generally lost less in parallel trials.
- Lifestyle context — every major trial delivered the drug on top of diet and physical-activity counseling, so trial timelines assume that background.
A person-to-person difference of months in reaching any given milestone is entirely consistent with the published data.
Research peptides: no real time-course data
For experimental compounds marketed for weight loss — AOD-9604, 5-amino-1MQ, and similar research peptides — the honest answer to "how long does it take" is that no one has published a credible timeline. These compounds lack the large, long-duration randomized trials that make GLP-1 timelines quotable; what exists is mostly preclinical work or small short studies that do not track weight over clinically meaningful periods. Any specific week-by-week promise attached to such products is extrapolation, not evidence.
That asymmetry is worth sitting with: the only peptides with a documented answer to this question are the regulated medicines — precisely because the answer took thousand-person trials running for more than a year to establish.